Objective: To review therapeutic strategies for the management of patients with steroid-induced hyperglycemia. Data Sources: A literature search of MEDLINE/PubMed (1990 to June 2017) was conducted using the search terms steroid, glucocorticoid, corticosteroid, hyperglycemia, and diabetes as well via review of literature citations. Study Selection and Data Extraction: Relevant clinical trials and case studies focusing on pharmacological interventions in humans were reviewed for inclusion. Articles discussing islet cell transplant were excluded. Data Synthesis: Hyperglycemia is a predictable adverse effect of glucocorticoid therapy, which is associated with negative outcomes, including an odds ratio of 1.36 for developing new-onset diabetes. A variety of strategies have been utilized for managing patients who are at risk of complications caused by steroid-induced hyperglycemia. Agents such as sulfonylureas, thiazolidinediones, meglitinides, metformin, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptidase-1 agonists, and insulin have been evaluated in case studies and small clinical trials with varying degrees of success. Conclusions: Since there are limited clinical data available to guide therapy, strategies that minimize the risk of adverse effects should be selected for the management of steroid-induced hyperglycemia. Therapies that may be safe and effective given current information include DPP-4 inhibitors, metformin, and weight-based neutral protamine Hagedorn insulin.
Introduction
BA is a 39-year-old man admitted to the hospital for acute decompensated heart failure. On exam, he complains of a sharp pain in his shoulder and is ultimately found to have a gout flare. He has a past medical history of recurrent gout flares despite chronic allopurinol therapy and uses colchicine intermittently. The hospital rheumatology service was consulted and provided recommendations for a steroid taper over several weeks starting with methylprednisolone 30 mg IV twice daily and quickly transitioned to oral prednisone. Once BA completed his taper, the plan was for him to receive maintenance therapy with prednisone 5 mg by mouth daily. The day after starting the steroid therapy, BA became hyperglycemic with blood glucoses ranging from 153 to 284 mg/dL. At this point, BA was initiated on the combination of insulin glargine 10 units subcutaneously once daily and insulin aspart sliding scale dosed 4 times daily. His blood glucose remained uncontrolled until he was discharged 4 days later without therapy to manage the hyperglycemia because his team was concerned about cost, compliance, and potential adverse effects. The decision to leave his hyperglycemia untreated prompted a review of the literature to determine the best practices for managing steroid-induced hyperglycemia in patients with and without a previous diagnosis of diabetes.
Glucocorticoids are used frequently in the hospital for a variety of indications, and similar to the case described above, steroid-induced hyperglycemia is common. In fact, it has been estimated that 40% to 56% of all inpatient consults to endocrinology services are for new or worsening diabetes caused by steroid initiation. 1 Failure to recognize the risks of hyperglycemia, even in those without diabetes, can negatively affect hospital outcomes. A prospective, observational study found a 16% in-hospital morality rate for those patients with new hyperglycemia compared with an in-hospital mortality rate of only 1.7% for those with normal glycemic control and 3% mortality rate for those with previously known diabetes and hyperglycemia (P < 0.001).
2 Untreated hyperglycemia resulting from steroid use can also be a trigger for developing diabetes. Oral steroid therapy is associated with an odds ratio of 1.36 for developing new-onset diabetes, as demonstrated in a large case-control series. 3 Furthermore, steroid use in elderly individuals has been shown to increase the risk of newonset diabetes with an odds ratio of 2.31 compared with those not receiving steroids. 4 The potential risk for serious adverse events, including increased in-hospital mortality and new-onset diabetes, with initiation of glucocorticoids should not be ignored by health care providers.
Data Sources
A literature search of MEDLINE/PubMed (1990 to June 2017) was conducted using the search terms steroid, glucocorticoid, corticosteroid, hyperglycemia, and diabetes as well via review of literature citations.
Mechanism of Glucocorticoid-Induced Hyperglycemia
There are a variety of mechanisms by which glucocorticoids cause hyperglycemia and worsen glycemic control. One of the primary mechanisms is by enhancing insulin resistance caused by skeletal muscle loss that occurs through protein breakdown and an increase in intracellular lipids and circulating free fatty acids, which interfere with glucose utilization. 5 Glucocorticoids have also been noted to interfere with insulin signaling by direct effects on both the insulin receptor and the glucose transporter 1, 5 as well as with the peroxisome proliferator-activated receptor (PPAR) signaling pathway. 6 Additionally, glucocorticoids promote gluconeogenesis by direct hepatic stimulation and by increasing insulin resistance because insulin is the primary suppressor of hepatic glucose production, especially in the presence of dietary glucose. 5 The result of the diabetogenic effects of glucocorticoids can be significant hyperglycemia, particularly in patients with some baseline insulin resistance, which typically manifests as elevated postprandial blood glucose. 7 Elevated postprandial blood glucose is only partially a result of the metabolic effects of glucocorticoids; it also corresponds temporally to the duration of action of the glucocorticoid administered, and these are compared in Table 1 . Administering prednisone, methylprednisolone, or dexamethasone with breakfast, as is commonly done in practice, would result in hyperglycemic effects around lunchtime because the onset of hyperglycemia is typically around 4 hours. The effects of prednisone or methylprednisolone would begin to wear off a few hours after dinner, whereas hyperglycemia caused by dexamethasone could last up to twice as long. 8 
Management of Steroid-Induced Hyperglycemia

Sulfonylureas and Thiazolidinediones
Many oral antidiabetic agents may be used to blunt the hyperglycemic effects of glucocorticoids; however, there are limited clinical trial data to guide their use for this indication. Sulfonylureas and thiazolidinediones were early candidates for treating steroid-induced hyperglycemia. Sulfonylureas were proposed because of their effects on prandial blood glucose and thiazolidinediones because they improve insulin sensitivity via PPAR agonism. 6 In the case of the sulfonylureas, Kasayama et al 9 observed the effect of glimepiride in 3 female patients receiving longstanding chronic steroids who were newly diagnosed with diabetes. The authors observed that after 4 weeks of glimepiride therapy, each patient demonstrated improved fasting blood glucose with an average of 126 mg/dL down from 227 mg/dL before sulfonylurea therapy, which was sustained for 24 weeks. Similarly, Willi et al 6 evaluated the use of the thiazolidinedione, troglitazone, in 7 female patients with longstanding steroid-induced hyperglycemia; the majority of patients were previously managed with insulin alone. After 5 to 8 weeks of adding troglitazone to their insulin regimen, 6 out of 7 patients were able to reduce their total daily insulin dose while demonstrating improved blood glucose control, as evidenced by a mild reduction in hemoglobin A 1C (7.4% vs 7.2%, P < 0.01). 6 Both these studies are limited by their small size, short duration, and lack of a control group.
Both the sulfonylureas and thiazolidinediones are less than ideal agents for management of steroid-induced hyperglycemia because of adverse effects. Sulfonylureas carry a risk of hypoglycemia and may have a longer duration of action than desired, whereas thiazolidinediones are associated with fluid retention, which could be exacerbated by glucocorticoids. Patients in the Willi et al 6 study gained an average of 2.6 kg during the 5 to 8 weeks of therapy with troglitazone.
Meglitinides
The meglitinides, including repaglinide and nateglinide, are insulin secretagogues similar to the sulfonylureas, although they are shorter-acting and focus on early-phase insulin secretion, potentially resulting in less hypoglycemia. Most of the data relating to the use of meglitinides for steroid-induced hyperglycemia is from patients after organ transplantation. In an observational study, 14 out of 23 patients with new-onset diabetes after a renal transplant were successfully treated with repaglinide. After 6 months, patients receiving repaglinide had reduced their A1C from a mean of 7.6% to 5.8% (P < 0.05). 10 The study has several limitations, including its observational design and limited external validity. Disadvantages of meglitinides include frequency of administration and cost, although their short duration of action may decrease the risk of hypoglycemia.
Metformin
Metformin may be a safer option even though published data evaluating its efficacy for use in steroid-induced hyperglycemia is limited. Among the oral antidiabetics, the mechanism of action of metformin most closely counteracts the effects of glucocorticoids by enhancing insulin sensitivity and reducing gluconeogenesis. In a small observational study conducted in pediatric acute lymphoblastic leukemia patients aged 2 to 15 years receiving steroids, the investigators demonstrated that metformin was effective in managing steroid-induced hyperglycemia. Metformin was continued until after corticosteroids were discontinued. Blood glucose was controlled in 12 out of 17 patients with metformin alone. Four patients required concomitant insulin, and only 1 patient failed metformin and was changed to insulin monotherapy. There were no episodes of hypoglycemia or severe toxicity associated with metformin use. 11 Similarly, a recent double-blind, placebo-controlled trial, in which adult patients initiated on glucocorticoid therapy were randomized to either metformin or placebo, suggested that metformin may reduce metabolic complications of patients requiring glucocorticoid treatment.
12 After 4 weeks of therapy, patients in the metformin group achieved lower median 2-hour prandial blood glucose (912 vs 1202 mmol/L/min, P = 0.005) compared with placebo. 12 Benefits of metformin include its low cost, its favorable weight profile, and limited risk for serious adverse events, most notably a low risk of hypoglycemia. This makes it a safer option to use during glucocorticoid tapers and for patients without a previous history of diabetes who may be less likely to test their blood glucose consistently.
Dipeptidyl Peptidase 4 Inhibitors and GlucagonLike Peptide 1 Agonists
Dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagonlike peptide 1 (GLP-1) receptor agonists are also potential options for the treatment of steroid-induced hyperglycemia, although there are limited data about their efficacy. Incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), are released by intestinal cells after eating and stimulate the pancreas to release insulin from β cells, and GLP-1 inhibits glucagon secretion from α cells, resulting in decreased postprandial blood glucose. 13, 14 DPP-4 is the enzyme responsible for degrading endogenous GLP-1; therefore, inhibiting this enzyme results in increased concentrations of GLP-1 and GIP and reduces hyperglycemia. 15 GLP-1 receptor agonists bind to the GLP-1 receptor but are more resistant to DPP-4 than endogenous GLP-1, and they improve insulin secretion, inhibit glucagon release, and slow gastric empyting. 16 The effectiveness of DPP-4 inhibitors and GLP-1 receptor agonists at lowering postprandial hyperglycemia make them viable options for treating steroid-induced hyperglycemia. Similar to metformin, both DPP-4 inhibitors and GLP-1 receptor agonists have a low risk of hypoglycemia because of their glucose-dependent action. The favorable side effect profile for DPP-4 inhibitors makes them preferable to injectable GLP-1 receptor agonists, which can cause significant gastrointestinal side effects.
A retrospective cohort study of 15 Japanese patients with diabetes on chronic glucocorticoid therapy who were prescribed sitagliptin for at least 6 months was conducted. Of the 15 patients, 5 were on sitagliptin monotherapy for steroid-induced hyperglycemia, 11 were also on a second oral antidiabetic agent, and 1 was also on insulin. Initiating sitagliptin was associated with an improvement in mean blood glucose from baseline (121 vs 195 mg/dL, P = 0.004), lower A1C (6.5% vs 7.6%, P < 0.001), and lower mean total body weight (58.9 vs 61.6 kg, P = 0.001). These reductions were more pronounced for those on monotherapy with sitagliptin, suggesting that DDP-4 inhibitors may be efficacious for steroid-induced hyperglycemia.
14 In contrast, a small, double-blind, placebo-controlled trial evaluating the effect of prednisolone 30 mg on glucose metabolism in 38 men with metabolic syndrome demonstrated that the addition of sitagliptin 100 mg did not prevent postprandial hyperglycemia from prednisolone. 13 Another small study evaluated 11 Japanese patients with chronic kidney disease who received renally dosed alogliptin for steroid-induced hyperglycemia. Alogliptin administration resulted in decreased postprandial hyperglycemia (P = 0.031), decreased A1C (P = 0.0033), and increased GLP-1 concentrations (P = 0.0014). 17 A short, randomized, double-blind, placebo-controlled, crossover study evaluating the use of the intravenous GLP-1 agonist, exenatide, in 8 healthy males on prednisone was conducted. Participants rotated through 3 therapeutic regimens for 2 days each: prednisone 80 mg daily plus intravenous exenatide, with a target serum concentration of 100 pg/mL; prednisone 80 mg daily plus saline; and placebo plus saline. The primary outcomes were measures of glucose tolerance, insulin secretion, and insulin sensitivity. Exenatide therapy significantly reduced 4-hour glucose area under the curve during a meal challenge test compared with placebo plus saline (P = 0.025), decreased insulin and glucagon levels after a meal (P = 0.017 and P = 0.018, respectively), and improved insulin sensitivity (P = 0.012). 16 Limitations of this study include the short duration, the dosing and route of exenatide administration, and the fact that it was conducted only with healthy participants. 16 
Insulin
Another option to treat steroid-induced hyperglycemia is insulin. Similar to the oral antidiabetic agents, there is limited clinical trial evidence to guide insulin therapy for this indication. Selection of an appropriate insulin regimen should be driven by several factors, including pharmacokinetic and pharmacodynamic properties (Table 2) , cost, and adherence.
Basal-bolus insulin, which is considered the most physiological regimen for the treatment of patients with diabetes, has also been evaluated in the treatment of steroid-induced hyperglycemia. In a cross-sectional study, the use of basalbolus insulin, consisting of both once-daily basal insulin and preprandial rapid-acting insulin given 3 times daily, was evaluated in 66 hospitalized patients with type 2 diabetes. The 24 patients receiving at least 10 mg/d of prednisolone had higher mean daily blood glucose compared with the 42 patients in the control group not receiving steroids (220 vs 180 mg/dL, P < 0.001) despite requiring a higher total daily dose of insulin. 18 This study suggests that patients with diabetes receiving steroids may not achieve adequate blood glucose control even with high doses of insulin. Additionally, traditional strategies of basal-bolus dosing or sliding scale insulin have several drawbacks. First, many patients who develop steroid-induced hyperglycemia are insulin naïve. The complexity of learning how to inject insulin and test blood glucose multiple times per day may be overwhelming, especially when only required for a short period of time. Second, this strategy is associated with a fairly high risk of hypoglycemia, both as the steroid effect wears off in the evening and as the steroid dose is tapered.
A preferred option for steroid-induced diabetes may be weight-based neutral protamine Hagedorn (NPH) insulin dosed once daily to be given at the same time as the steroid. This strategy is advantageous because the duration of action of NPH closely mimics that of prednisone, reducing the risk of hypoglycemia as the steroid effects wear off. Additionally, insulin resistance has been shown to increase in a linear manner with body weight for patients with a body mass index over 26.8 kg/m 2 , suggesting that a weight-based approach may be warranted. 19 A retrospective analysis evaluating the use of NPH insulin compared with insulin glargine in 120 patients with prednisone-associated diabetes was conducted and found that there was no difference between groups in mean fasting blood glucose, mean or median daily blood glucose, and incidence of hypoglycemia despite patients in the NPH group receiving a lower weight-based dose (0.27 vs 0.34 U/kg, P = 0.04) and lower doses of correctional insulin. 20 Presumably, this difference is a result of NPH insulin peaking around the same time that prednisone causes its highest degree of hyperglycemia. NPH insulin is a preferable strategy for insulin-naïve patients because of the simplicity of a once-daily dosing strategy, elimination of meal-time insulin, and no difference in glycemic control compared with insulin glargine. For patients receiving twice-daily prednisone dosing or dexamethasone, it may be reasonable to substitute insulin glargine or insulin detemir for NPH insulin in order to mirror the longer duration of hyperglycemia.
One recommendation is to initiate weight-based NPH insulin at 0.1 U/kg for every 10-mg of prednisone up to a maximum of 0.4 U/kg 8 ; therefore, if an 80-kg patient were to receive prednisone 30 mg once daily, he or she could be initiated on 24 units of NPH subcutaneously once daily. Patients already receiving insulin at home should add the weight-based total to their normal basal insulin dose. Patients can be instructed to reduce their insulin dose by 0.1 U/kg for every 10-mg reduction in prednisone dose. When insulin is tapered concomitantly with steroids, patients should receive detailed verbal and written education by the pharmacist to improve their understanding of these complex regimens.
Regarding the case of BA discussed at the beginning, a DPP-4 inhibitor or metformin would have been a reasonable option for managing his steroid-induced hyperglycemia after discharge from the hospital. Because he did not have diabetes and was unfamiliar with both blood glucose monitoring and insulin administration, insulin therapy would not be ideal. Benefits to using a DPP-4 inhibitor include a low risk for hypoglycemia, a favorable side effect profile, and ease of use, although cost concerns may be an issue for patients without prescription insurance. Metformin is a less-expensive agent that could be dosed once daily at the same time as prednisone to maximize adherence and would not require frequent blood glucose monitoring, because of the low risk of hypoglycemia. Other oral options, such as sulfonylureas or thiazolidinediones, would not be good choices for this patient. Sulfonylureas have a higher risk of hypoglycemia and an increased risk of weight gain, and meglitinides would require multiple daily dosing and are not commonly used anymore. Additionally, thiazolidinediones have an increased risk of fluid retention and worsening heart failure. These disadvantages make each of these medications inappropriate for this patient.
Conclusion
Complications associated with steroid-induced hyperglycemia are often underestimated despite hyperglycemia being a well-known adverse effect of glucocorticoid therapy. Appropriate management of hyperglycemia in patients with and without a history of diabetes by utilizing an oral antidiabetic agent, such as a DPP-4 inhibitor or metformin, or by using the weight-based NPH insulin may reduce the risk of adverse outcomes, including symptomatic hyperglycemia and new-onset diabetes.
